A phase II study of nimustine hydrochloride, cisplatin, and etoposide combination chemotherapy for supratentorial malignant gliomas

Citation
T. Beppu et al., A phase II study of nimustine hydrochloride, cisplatin, and etoposide combination chemotherapy for supratentorial malignant gliomas, J NEURO-ONC, 49(3), 2000, pp. 213-218
Citations number
18
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology
Journal title
JOURNAL OF NEURO-ONCOLOGY
ISSN journal
0167-594X → ACNP
Volume
49
Issue
3
Year of publication
2000
Pages
213 - 218
Database
ISI
SICI code
0167-594X(200009)49:3<213:APISON>2.0.ZU;2-W
Abstract
Twenty-eight patients who were previously treated by aggressive surgery and radiation and were diagnosed with supratentorial malignant gliomas receive d a combination of nimustine hydrochloride; 1-(4-amino-2-methyl-5-pyrimidin yl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU), cisplatin and etoposide (ACE therapy) as primary treatment. Cisplatin and etoposide w ere given at doses of 20 and 60 mg/m(2)/day for 5 days, respectively, ACNU doses 80 mg/m(2)/day on the first day. Treatment was repeated at 4-week int ervals for up to 3 cycles. Seventeen patients (60.7%) complained of nausea. Grade 3 or 4 hematological toxicity occurred in 11 patients (39.3%), and g rade 3 or 4 renal toxicity occurred in 2 patients. The percentage of patien ts who showed complete or partial response was 28.6% (8/28). The median tim e of tumor progression was 40 weeks, and the median survival time was 146 w eeks. There were some long-surviving patients who may have benefited from A CE combination. This study demonstrated the effects of ACE combination in p atients with supratentorial malignant gliomas.